1. Byakangelicol may inhibit P-gp expressed at the BBB even under in vivo conditions. 2. Byakangelicol can inhibit IL-1beta-induced PGE2 release in A549 cells, this inhibition may be mediated by suppression of COX-2 expression and the activity of COX-2 enzyme, thus it may have therapeutic potential as an anti-inflammatory drug on airway inflammation.
Molekulargewicht:
316.31
Reinheit:
99.55%
CAS Nummer:
[26091-79-2]
Formel:
C17H16O6
Target-Kategorie:
COX
T6S0077
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten